Compare INLX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | ANTX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 36.7M |
| IPO Year | 2013 | 2022 |
| Metric | INLX | ANTX |
|---|---|---|
| Price | $7.67 | $5.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 888.0 | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,336.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.50 | $1.00 |
| 52 Week High | $15.72 | $6.91 |
| Indicator | INLX | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 87.89 |
| Support Level | $7.50 | $1.05 |
| Resistance Level | $8.29 | N/A |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 25.00 | 65.45 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.